Table 1.

Roundtable and Panel Discussion Questions

Focus area	Roundtable and panel discussion questions
Standards	What are the key deficiencies in existing iPSC and ESC standardization efforts, and how can we best act to harmonize these efforts?
Biomanufacturing	What are the key outstanding challenges as we seek to remove the “art” and cost from the manufacture of iPSC therapies?
Strategic partnerships	Which models for strategic partnerships are accelerating stem cell translation most effectively? And for those that are not, why not?
Regulatory and intellectual property	Building on community experience with ASCs, what regulatory uncertainties remain with respect to ESCs and what additional uncertainties are perceived for iPSCs?
Clinical adoption	Failure to demonstrate sufficient efficacy represents a major barrier to the adoption of existing cellular therapeutics. What steps (and data) are required to confer stakeholder confidence and successful adoption?

ASCs, adipose-derived stem cells; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells.